ACTX 101
Alternative Names: ACTX-101; ACTX-102Latest Information Update: 04 Apr 2024
At a glance
- Originator Alcyone Lifesciences
- Developer Alcyone Therapeutics
- Class Gene therapies
- Mechanism of Action Gene transference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Rett syndrome; Unspecified
Most Recent Events
- 04 Apr 2024 Preclinical trials in Unspecified in USA (unspecified route) prior to April 2024 (Alcyone Therapeutics pipeline, April 2024)
- 04 Apr 2024 Alcyone Lifesciences plans to file an IND application to initiate clinical trial (Alcyone Lifesciences pipeline, April 2024)
- 18 May 2022 Pharmacodynamics and adverse events data from a preclinical trials in Rett syndrome released by Alcyone Therapeutics